€9.3m · Series A · Healthtech · Barcelona, Spain
Barcelona-based Onalabs has closed a €9.3m investment round to scale devices that monitor physiological signals through sweat and skin. The Spanish Society for Technological Transformation (SETT) contributed €4.6m through the Next Tech facility, with 1921 Ventures, nPrime, Reig Patrimonia and WA4STEAM also participating. Onalabs says the capital will support industrialisation and commercialisation of ONASPORT, clinical and regulatory validation of ONAVITAL, its diabetes programme, local manufacturing and international expansion.
Industrialisation is the commercial milestone
ONASPORT is a chest-strap wearable for athletes and coaches. The company says it tracks sweat-inferred lactate, dehydration, electrolyte loss, heart rate and sweat rate, sending readings to a dashboard and Garmin devices. Each session also uses an ONAS10 single-use sweat card, so the product combines durable hardware, a recurring consumable and a software layer rather than relying on a one-off device sale.
ONASPORT is already in the commercial phase. The financing therefore backs the shift from a validated product to repeatable production and distribution. Manufacturing more units is only part of that job: Onalabs must produce sensors and disposable cards consistently, integrate the data into training workflows and give coaches a reason to keep using the system across sessions.
That model can create continuing revenue through consumables and software-supported use, but it also exposes the company to execution across several components. A reliable sensor without a usable dashboard, or a strong interface without consistent disposable cards, would weaken the whole product. The company’s work with FC Barcelona and Garmin gives it relevant product-development and interoperability relationships; adoption will still depend on performance in routine training environments.
The same platform has a second regulatory path
ONAVITAL applies the monitoring platform to healthcare, measuring vital signs including blood pressure, heart rate, oxygen saturation and skin temperature. Unlike ONASPORT, it remains in clinical and regulatory validation. Cinco Días reported that Onalabs was running pilots with more than ten hospitals when the round was announced.
The distinction matters commercially. Sports customers can buy and use ONASPORT now, while ONAVITAL must build clinical evidence and clear regulatory requirements before it can scale through healthcare providers. The €9.3m round is financing both paths at once: manufacturing and sales execution for one product, and evidence generation for another.
Onalabs reported a team of 30 and six patents at the time of the financing. It is also developing a diabetes-related line, extending the same premise that sweat and skin can provide continuous data beyond isolated measurements. The wider platform opportunity will depend on whether the company can turn one commercial product into repeatable demand while keeping the clinical programme rigorous enough for hospitals and regulators.
